Anavex have no longer patent protection to replace the original Vamvakides patent on A2-73 in it current form for standalone treatment.
If Anavex has insufficient rights to the commercial use of their sigma-1 receptor activators (blarcamesine, etc.) and this is a legitimate risk, are the institutional owners of millions of shares of AVXL ignorant of such? Why haven’t they perceived these putative risks? For most of us retail owners of AVXL shares our losses will be in the tens of thousands of dollars when Anavex goes bust. But for the stock funds, they own millions of dollars of the stock. Gonna be big losses for them. They're probably not as smart or informed as all of us who post here are, right?